XGene Regulatory Intelligence Platform
Connect enforcement signals to quality systems, services, expert commentary, and implementation resources.
The FDA's 2011 Process Validation Guidance was written for the pharmaceutical industry. Applying it to a GT vector manufacturing process requires translation — and where that translation is missing, PPQ failures follow.
View details →
In July 2025, FDA released 202 redacted Complete Response Letters covering approvals from 2020 through 2024 — followed by 89 more on September 4, 2025 — and the aggregate picture is unambiguous: 74 percent
View details →
Every gene therapy program changes its manufacturing process. The question is not whether you will need a comparability exercise — it is whether you will have the analytical foundation to execute it.
View details →
ICH Q12 has been final guidance in the United States since 2021, and FDA has published implementation considerations for FDA-regulated products. Yet the majority of marketed drug product CMC packages were approved under the
View details → Most gene therapy programs enter Phase 3 with CMC packages designed for Phase 1. The cost of catching up — analytically, regulatorily, and temporally — is measured in months and millions.
View details → Every Post-Approval Change Management Protocol is written as if it will be approved. Most of them earn the filing category they were designed to avoid. The PACMP is not approved because it describes anticipated
View details → The analytical methods used to release and characterize a gene therapy vector are unlike any other in the pharmaceutical industry. Validating them to ICH Q2(R2) standards requires a GT-specific strategy that most CROs and
View details → The FDA Process Validation Guidance of 2011 applies to biological drug substances as directly as it applies to small molecules — but the biological complexity of upstream cell culture processes makes Stage 1 process
View details →
EMA's Product Management Service assigns the EU product identifier that is required in electronic product information and variation submissions — and managing this identifier accurately across a complex product portfolio is a regulatory operations
View details → ICH Q6B — Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products — defines the characterization framework for biologic drug substances that has been in force since 1999. Despite its age, it remains the
View details → ISO 11615 is the international standard that defines how medicinal products are uniquely identified globally — and understanding its data model is the key to understanding why EMA's SPOR system works the way it
View details → The impurity framework for biologic drug substances is categorically different from the ICH Q3A small molecule framework — and applying Q3A logic to a biologic impurity profile is the mistake that generates the most
View details → A pharmaceutical company that does not have UNII registrations for all of its active substances has a regulatory data foundation problem that will surface at every submission — FDA, EMA, and the global IDMP
View details → CDISC standards — the Clinical Data Interchange Standards Consortium — are well established in clinical trial data management, but their intersection with pharmaceutical CMC is less understood and increasingly relevant as FDA and EMA
View details → A protein drug formulation development package that runs one pH condition, one temperature, and calls the stability program complete is not a formulation development package — it is a stability confirmation exercise wearing the
View details → Every pharmaceutical company that has committed to FAIR data principles has a beautiful diagram showing how their CMC data will be Findable, Accessible, Interoperable, and Reusable — and most of them discover during implementation
View details → A high-concentration antibody formulation isn't a standard mAb formulation scaled up in concentration — above roughly 100 mg/mL, viscosity becomes a manufacturability and deliverability constraint in its own right, not a formulation footnote. An
View details → The manual, document-centric process of assembling a CMC regulatory submission — exporting data from LIMS, pasting it into Word tables, formatting it for eCTD, and cross-referencing it across Module 3 sections — is being
View details →